Zystor
Privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal.
Employees
Enterprise value
$115m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor investor | €0.0 | round | |
$115m Valuation: $115m | Acquisition | ||
| Total Funding | 000k | ||
Stonehenge Capital(exited)
Hexagon Investments(exited)
Venture Investors(exited)
Mason Wells(exited)
Prolog Ventures(exited)
Apjohn ventures(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads